We are seeking a strong, method-oriented statistical geneticist and/or quantitative geneticist to join Biogen’s Statistical Genetics and Genetic Epidemiology team. This team is responsible for providing genetics and genomics expertise to the R&D organization with a focus on developing and applying cutting-edge genetic approaches to support early target discovery and validation.
Effective use of disruptive technologies is at the heart of Biogen’s strategy to discover and develop highly differentiated medicines. We are investing in human genetics and genomics, digital technologies and advanced analytics to address scientific questions that will improve the discovery and development of the next generation of therapeutics. The Translational Biology Organization in Research and Early Development at Biogen is responsible for providing and analyzing genetic, genomic, cellular and in vivo data to support target validation and the therapeutic rationale for Biogen’s drug discovery research teams and clinical development programs.
The incumbent will be a human geneticist, biostatistician or epidemiologist who has multi-year hands-on experience on how to develop or apply statistical genetic principles and methods to analyze large population or familial genetic data sets, electronic health records, clinical data, and/or laboratory data for interrogating complex phenotypes. A track record of active participation in academic consortia, public-private partnerships or multi-partner industry collaborations, ideally with having had leading roles, is desired. Experience in Biogen’s focus area of neurological, neurodegenerative diseases and neuropsychiatry or associated intermediate phenotypes will be a plus.
Biogen has made substantial investments in external partnerships and collaborations and a focus of the Statistical Genetics and Genetic Epidemiology team will be how to best leverage these resources. This includes leveraging data from the UK Biobank Life Sciences Consortium (that by 2019 will have generated whole-exome sequencing data on 500,000 UK Biobank participants), FinnGen (a precompetitive partnership generating genotypes on 500,000 Finns with longitudinal health data), Open Targets (a platform to integrate supporting evidence for the suitability of genes as drug targets), as well as other public and proprietary resources to initiate novel and enhance existing drug development programs.
The incumbent will work in an experienced team of statistical geneticists and closely collaborate with researchers in the broader Translational Biology group, therapeutic area scientists, clinical researchers, and other interested parties to identify the most relevant opportunities to influence decisions and increase our probability of success in developing new medicines to diseases of the highest medical need. This will include close interactions with functional genomics scientists and biologists to design laboratory experiments to determine the molecular and cellular-level function of genetic findings, as well as early/late stage clinical development leaders to inform human studies with genetic data.
The Scientist for Statistical and Quantitative Genetics will be expected to:
Establish and use advanced statistical genetic and genetic epidemiological analytical techniques with the aim to discover and validate drug targets and biomarkers, and to identify mechanisms of action based on human data.
Be responsible for ensuring Biogen is at the forefront of statistical genetics, establishing best practices and standards, and the development and execution of statistical genetics plans to support Biogen’s R&D programs.
Contribute expertise on human genetic data to support Biogen’s broader human knowledge base.
Take on leadership functions for external collaborations that ensure the human genetics capabilities and resources remain on the leading edge of emerging new technologies and analytical approaches.
Several years of post-graduate experience analyzing biological and/or medical data sets
Expertise in the field of statistical genetics and working knowledge of emerging approaches to best utilize human genetic data, for example, quantitative trait analysis, multi-phenotype analysis, Mendelian Randomization methods, or genetic risk score methodologies
Demonstrated ability to work collaboratively within research project teams
Excellent communication and presentation skills. Ability to translate complex statistical/informatics terminology in such a way that scientifically trained individuals can readily understand their significance
Expertise in working with complex phenotype data, such as electronic medical records (EMRs) or image data
Knowledge of the pharmaceutical drug discovery and development process with experience in pre-clinical and/or clinical drug development
Ph.D., M.D., or M.D./Ph.D. in a relevant scientific discipline
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Biogen also manufactures and commercializes biosimilars of advanced biologics. Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options. One of the pioneers in biotechnology, Biogen was founded in 1978 and today serves patients in nearly 90 countries. Our global headquarters and R&D operations are located in Cambridge, Massachusetts, with an international headquarters in Zug, Switzerland, world-class manufacturing facilities in Research Triangle Park, North Carolina, USA and Hillerod, Denmark, and affiliate locations arou...nd the world.
We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry. To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments. For nearly two decades Biogen has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world. Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease. We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer’s disease, Parkinson’s disease, and ALS. As we uncover new insights into human biology, Biogen is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders. Biogen is revolutionizing biologics manufacturing, developing the industry’s most advanced plants and processes. This expertise is used to produce both original innovative therapies and biosimilars that expand patient access to lower-cost medicines.